GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance And Increases RVR Rates In Phase 2 Clinical Trial

Four-week Phase 2 clinical trial data show that GI-5005, GlobeImmune’s hepatitis C virus (HCV) targeted molecular immunogen (Tarmogen(R)), doubled viral clearance overall and in all major subgroups and doubled the rapid virologic response (RVR) rate in naive patients with high viral load. The study compared GI-5005 plus standard of care (SOC) — pegylated-interferon plus ribavirin — versus SOC alone in patients with chronic genotype 1 hepatitis C infection.

More: continued here

Filed under: Clinical Trials on November 3rd, 2008